Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PhoreMost, inStem enter structural biology alliance
CCBT at the Institute for Stem Cell Science and Regenerative Medicine (inStem) is funded by the Department of Biotechnology, Government of India. The aim of the collaboration is
CCBT at the Institute for Stem Cell Science and Regenerative Medicine (inStem) is funded by the Department of Biotechnology, Government of India. The aim of the collaboration is
Pfizer and Sangamo Therapeutics revealed updated results from the Phase 1/2 Alta study, which demonstrated that SB-525 was generally well-tolerated and showed a dose-dependent increase in Factor VIII
Here, CAN04 is examined as monotherapy or in chemotherapy combinations in patients with non-small cell lung cancer (NSCLC) or pancreatic cancer (PDAC). All 20 patients planned for one
According to the company, Xembify (immune globulin subcutaneous, human- klhw) is a 20% immune globulin solution for subcutaneous injection indicated to treat primary humoral immunodeficiency (PI) in patients
Dovato is a new once-daily, single-pill and two-drug regimen approved for the treatment of HIV-1 infection in adults and adolescents above 12 years of age weighing at least
“While there is no cure for multiple myeloma, there are FDA-approved treatments to target the cancer and slow down the spread of the disease. Sadly, often over time,
The medicine will become available immediately in 13 countries across Europe on the day the reference medicine loses market exclusivity. Sandoz will continue to expand to other countries
The study has showed that Xofluza was well tolerated in children with flu. It also demonstrated that Xofluza is comparable to oseltamivir, a proven effective treatment for children
Neratinib was originally approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer,
The sale of Xiidra has also provided an option to Takeda to receive up to an additional $1.9bn (£1.5bn) in potential milestone payments from Novartis. Takeda intends to